Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1161 participants.
Also called NCT01599104
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,161 participants
- Sponsor
- Registry
-
NCT01599104
-
- Other papers using this trial's data
- Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01599104. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2015-08-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- LCZ696
- Intervention (Drug)
- Olmesartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01599104- Content hash
25ae9f8aace3621634b726f672b34abdf0e72eb5e0e5260437328db4798ab7ff